Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
December 18, 2025
Eiger BioPharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
August 5, 2021
Related Post
-
-
Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point
December 17, 2025
-
Iterum Therapeutics Provides Business Update
December 17, 2025
-
Devonian Health Group Reports Financial Results of its First Quarter Ended on October 31, 2025 and Provides Corporate Update
December 12, 2025